Beijing Konruns Pharmaceutical Co Ltd Net Asset Quality Index
Beijing Konruns Pharmaceutical Co Ltd net asset quality index. Beijing Konruns Pharmaceutical Co Ltd (603590) has a Net Asset Quality Index of 86.0% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥4.08 Billion minus total liabilities of CN¥569.41 Million yields net assets of CN¥3.51 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See shareholders equity of Beijing Konruns Pharmaceutical Co Ltd for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Beijing Konruns Pharmaceutical Co Ltd (2013–2025)
Net asset quality index of Beijing Konruns Pharmaceutical Co Ltd from 2013 to 2025. This chart shows how Beijing Konruns Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 86.0%, representing net assets of CN¥3.51 Billion against total assets of CN¥4.08 Billion CNY. Check 603590 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Beijing Konruns Pharmaceutical Co Ltd Net Asset Quality Index by Year (2013–2025)
Beijing Konruns Pharmaceutical Co Ltd net asset quality index by year from 2013 to 2025. The table below presents the year-by-year Net Asset Quality Index for Beijing Konruns Pharmaceutical Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 603590 stock market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 85.4% | CN¥3.50 Billion | CN¥4.09 Billion | CN¥598.51 Million | ▼ -2.0 pp |
| 2024 | 87.4% | CN¥3.43 Billion | CN¥3.92 Billion | CN¥493.52 Million | ▼ -1.5 pp |
| 2023 | 88.9% | CN¥3.36 Billion | CN¥3.78 Billion | CN¥418.44 Million | ▼ -4.2 pp |
| 2022 | 93.1% | CN¥3.19 Billion | CN¥3.42 Billion | CN¥234.68 Million | ▲ +0.3 pp |
| 2021 | 92.9% | CN¥3.13 Billion | CN¥3.37 Billion | CN¥240.74 Million | ▲ +11.4 pp |
| 2020 | 81.5% | CN¥3.08 Billion | CN¥3.79 Billion | CN¥701.72 Million | ▼ -4.5 pp |
| 2019 | 86.0% | CN¥2.73 Billion | CN¥3.17 Billion | CN¥445.84 Million | ▲ +1.0 pp |
| 2018 | 85.0% | CN¥2.48 Billion | CN¥2.92 Billion | CN¥439.48 Million | ▲ +4.0 pp |
| 2017 | 81.0% | CN¥1.36 Billion | CN¥1.67 Billion | CN¥318.93 Million | ▼ -4.6 pp |
| 2016 | 85.6% | CN¥874.92 Million | CN¥1.02 Billion | CN¥147.37 Million | ▲ +4.8 pp |
| 2015 | 80.8% | CN¥683.27 Million | CN¥845.80 Million | CN¥162.53 Million | ▲ +7.4 pp |
| 2014 | 73.4% | CN¥488.02 Million | CN¥665.04 Million | CN¥177.02 Million | ▲ +12.5 pp |
| 2013 | 60.8% | CN¥313.45 Million | CN¥515.13 Million | CN¥201.68 Million | — |